空军医学杂志
空軍醫學雜誌
공군의학잡지
MEDICAL JOURNAL OF AIR FORCE
2015年
1期
17-19,22
,共4页
杨彩哲%刘朝阳%徐先荣%刘红巾%郑军%刘晶%付兆君%熊巍%关小宏%王建昌
楊綵哲%劉朝暘%徐先榮%劉紅巾%鄭軍%劉晶%付兆君%熊巍%關小宏%王建昌
양채철%류조양%서선영%류홍건%정군%류정%부조군%웅외%관소굉%왕건창
甲状腺功能亢进症%131I%抗甲状腺药物%治疗%飞行员
甲狀腺功能亢進癥%131I%抗甲狀腺藥物%治療%飛行員
갑상선공능항진증%131I%항갑상선약물%치료%비행원
Hyperthyroidism%131I%Antithyroid drug%Therapy%Pilots
目的：评价131I和抗甲状腺药物（antithyroid drug，ATD）治疗飞行员甲状腺功能亢进（甲亢）的疗效及对医学鉴定的影响。方法回顾分析空军总医院2000年12月—2014年12月间住院的甲亢飞行员30例的临床资料，按照治疗方式不同分为131I治疗组及ATD治疗组。主要研究终点：停飞率；次要研究终点：合格率、平均治疗时间、复发率。结果30例中，131I治疗组4例：2例飞行合格，2例暂时飞行不合格，无停飞病例；ATD治疗组26例：7例飞行合格，4例暂时飞行不合格，15例停飞，停飞率为57.69%。131I治疗组的2例飞行合格的飞行员平均地面观察时间6.5个月（6～7个月）；ATD治疗组的7例飞行合格的飞行员平均地面观察时间则长达23.25个月（11～69个月）。131I治疗组1例复发，复发率25.00%；ATD治疗组有3例复发，复发率23.08%。结论飞行员患甲亢用ATD治疗，停飞率高，恢复飞行者治疗周期和地面观察时间长，建议将131I作为首选治疗，以缩短治疗时间，降低停飞率。
目的：評價131I和抗甲狀腺藥物（antithyroid drug，ATD）治療飛行員甲狀腺功能亢進（甲亢）的療效及對醫學鑒定的影響。方法迴顧分析空軍總醫院2000年12月—2014年12月間住院的甲亢飛行員30例的臨床資料，按照治療方式不同分為131I治療組及ATD治療組。主要研究終點：停飛率；次要研究終點：閤格率、平均治療時間、複髮率。結果30例中，131I治療組4例：2例飛行閤格，2例暫時飛行不閤格，無停飛病例；ATD治療組26例：7例飛行閤格，4例暫時飛行不閤格，15例停飛，停飛率為57.69%。131I治療組的2例飛行閤格的飛行員平均地麵觀察時間6.5箇月（6～7箇月）；ATD治療組的7例飛行閤格的飛行員平均地麵觀察時間則長達23.25箇月（11～69箇月）。131I治療組1例複髮，複髮率25.00%；ATD治療組有3例複髮，複髮率23.08%。結論飛行員患甲亢用ATD治療，停飛率高，恢複飛行者治療週期和地麵觀察時間長，建議將131I作為首選治療，以縮短治療時間，降低停飛率。
목적：평개131I화항갑상선약물（antithyroid drug，ATD）치료비행원갑상선공능항진（갑항）적료효급대의학감정적영향。방법회고분석공군총의원2000년12월—2014년12월간주원적갑항비행원30례적림상자료，안조치료방식불동분위131I치료조급ATD치료조。주요연구종점：정비솔；차요연구종점：합격솔、평균치료시간、복발솔。결과30례중，131I치료조4례：2례비행합격，2례잠시비행불합격，무정비병례；ATD치료조26례：7례비행합격，4례잠시비행불합격，15례정비，정비솔위57.69%。131I치료조적2례비행합격적비행원평균지면관찰시간6.5개월（6～7개월）；ATD치료조적7례비행합격적비행원평균지면관찰시간칙장체23.25개월（11～69개월）。131I치료조1례복발，복발솔25.00%；ATD치료조유3례복발，복발솔23.08%。결론비행원환갑항용ATD치료，정비솔고，회복비행자치료주기화지면관찰시간장，건의장131I작위수선치료，이축단치료시간，강저정비솔。
Objective To evaluate the efficacy of 131I and antithyroid drug therapy for the hyperthyroidism disease in pilots and its impact on medical evaluation, summarizing the experience in aviation medicine. Methods The pilots with hyperthyroidism inpatients in the General Airforce Hospital from December 2000 to December 2014 were reviewed, the patients were divided into two groups: the 131I therapy group and the control group (antithyroid drugs treatment group). The main endpoint was disqualified rate. The second endpoint was qualified rate, the average treatment time and relapse rate. Results Among 30 cases of hyperthyroidism diseases: four cases with radioactive 131I therapy group: two cases were finally flying qualified, two cases were assessed as temporary grounding, disqualified rate was 0; among 26 cases of antithyroid drug treatment groups, 7 cases were finally flying qualified, while other 4 cases and 15 cases were respectively assessed as temporary and permantent grounding, disqualified rate was 57.69%. The 2 cases of 131I therapy group flight qualified of flying observation time average 6.5 months (6 to 7 months ); 7 cases of antithyroid drug therapy group flight qualified of flying with an average observation time was up 23.25 months (11 to 69 months). With one case in 131I therapy group of recurrence of hyperthyroidism, the relapse rate was 25%, the relapse rate of control group was 23.08%. Conclusions Pilots suffering from hyperthyroidism with antithyroid treatment has a higher disqualified rate and longer treatment period and ground observation time. 131I therapy can be recommended as the preferred treatment for pilots with hyperthyroidism, in order to shorten the treatment time and reduce the flight disqualified rate.
